Rocket Lab's Ascent: Strong Results Tempered by Development Delays

Rocket Lab posts record revenue and a $1.85B backlog, but a major rocket program delay introduces uncertainty for investors. Analysts adjust price targets.

Rocket Lab USA continues to demonstrate robust operational execution, yet a significant project delay presents a persistent challenge for investors. While record financials and major defense contracts bolster the investment thesis, a setback in a key rocket program introduces fresh uncertainty. The central question is whether the company's growth trajectory can withstand this latest schedule shift.

Operational Momentum and Record Backlog

The company closed its 2025 fiscal year on a high note, posting unprecedented financial results. Annual revenue reached a record $602 million, marking a 38% year-over-year increase. Perhaps more indicative of future strength, the contract backlog surged 73% to $1.85 billion. This substantial pipeline suggests that future business is growing at a faster rate than current operations.

The fourth quarter performance further solidified this positive trend. Rocket Lab reported a loss per share of $0.09, slightly better than anticipated, while quarterly revenue of approximately $180 million also exceeded estimates. A key efficiency metric showed marked improvement, with the adjusted (Non-GAAP) gross margin expanding significantly from 32% to 44.3%.

Looking ahead, management provided first-quarter 2026 revenue guidance of $185 to $200 million, surpassing the analyst consensus estimate of around $180.9 million. However, a note of caution was introduced regarding profitability; the forecast for adjusted gross margin is set between 39% and 41%, below the exceptional level achieved in Q4.

Wall Street's Mixed Adjustments

The strong annual figures prompted reactions from Wall Street analysts, though their assessments varied. On March 2, 2026, Cantor Fitzgerald raised its price target to $85 from $72, maintaining an "Overweight" rating. The firm cited the record 2025 revenue that outperformed both expectations and the company's own earlier forecast.

In contrast, Needham & Company maintained its "Buy" recommendation but reduced its price target on February 27, 2026, moving from $110 to $95. This divergence highlights that while the overall direction is positive, the valuation and perceived risks are being weighted differently across the market.

Launch Cadence and Defense Focus Provide Stability

A high launch frequency underscores Rocket Lab's operational capabilities. The company completed 21 successful missions in 2025, including a record seven in the fourth quarter alone. The momentum continued into early 2026 with another successful mission, marking the fourth launch of the year and the second within a single week—conducted from different countries.

The company's backlog reveals a heavy reliance on national security programs. As of Q4 2025, 74% of the secured backlog was attributed to "Space Systems" with 26% for "Launch" services. A standout contract is the SDA Tranche 3 award, which holds a potential total value of up to $805 million and stands as the largest in company history. Management expects to recognize approximately 37% of the total backlog as revenue within the next twelve months.

The Neutron Delay: A Persistent Headwind

The primary source of uncertainty remains the Neutron medium-lift rocket program. Following a test issue involving a crack in a first-stage tank, the target date for the inaugural launch has been pushed back to the fourth quarter of 2026. This delay implies increased near-term development costs, extended timeline risk, and consequent pressure on investor sentiment and margin expectations.

This tension is reflected in the share price movement. The stock closed at $70.11 on Friday, registering a decline of 3.06% over the preceding 30 days.

Insider Activity and Institutional Investment

Between March 2 and March 4, 2026, several insider transactions were reported, involving sales of shares by the CEO, CFO, and other executives. While such sales can be routine, a cluster of them can temporarily increase the supply of shares on the market, potentially applying short-term downward pressure on the price.

Conversely, major institutional investors were expanding their holdings during the fourth quarter. Vanguard increased its position by 13.4% to 47,420,192 shares, while Baillie Gifford & Co. boosted its stake by 47.2% to 17,851,446 shares.

Attention now turns to the next major milestone: the first-quarter 2026 results, due on May 13, 2026. This report will serve as a critical test of whether Rocket Lab can sustain its high revenue tempo without the Neutron delay exerting more margin pressure than currently anticipated.